Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by New Republic Capital LLC

New Republic Capital LLC decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.6% during the 4th quarter, Holdings Channel reports. The firm owned 827 shares of the medical research company’s stock after selling 119 shares during the quarter. New Republic Capital LLC’s holdings in Thermo Fisher Scientific were worth $431,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Stonebridge Financial Group LLC acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at about $103,000. Violich Capital Management Inc. boosted its position in Thermo Fisher Scientific by 13.7% in the 4th quarter. Violich Capital Management Inc. now owns 1,152 shares of the medical research company’s stock valued at $599,000 after buying an additional 139 shares during the last quarter. Sapient Capital LLC grew its holdings in Thermo Fisher Scientific by 35.9% during the 4th quarter. Sapient Capital LLC now owns 1,715 shares of the medical research company’s stock worth $893,000 after acquiring an additional 453 shares in the last quarter. Panoramic Capital Partners LLC acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at about $218,000. Finally, Arlington Partners LLC raised its stake in Thermo Fisher Scientific by 4.6% during the fourth quarter. Arlington Partners LLC now owns 6,958 shares of the medical research company’s stock valued at $3,620,000 after buying an additional 307 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the transaction, the executive vice president now owns 16,363 shares in the company, valued at $9,582,009.17. This trade represents a 1.80 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the sale, the chief executive officer now directly owns 111,192 shares of the company’s stock, valued at $58,960,669.92. This represents a 8.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 20,125 shares of company stock valued at $11,231,699. Corporate insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on TMO shares. StockNews.com upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Evercore ISI dropped their target price on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Bank of America lowered their price objective on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Citigroup lifted their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company a “neutral” rating in a research note on Friday, January 31st. Finally, UBS Group increased their price target on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a research report on Friday, January 31st. Four investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $658.00.

Thermo Fisher Scientific Stock Down 3.2 %

Shares of TMO stock opened at $553.02 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The stock has a market cap of $211.53 billion, a PE ratio of 33.46, a price-to-earnings-growth ratio of 3.18 and a beta of 0.77. The business’s fifty day moving average is $547.34 and its 200-day moving average is $572.24. Thermo Fisher Scientific Inc. has a 1 year low of $493.30 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has initiated a stock repurchase program on Friday, November 15th that allows the company to repurchase $4.00 billion in shares. This repurchase authorization allows the medical research company to purchase up to 2% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.